Altamira Therapeutics CYTOF Cash Flow Statement (2013-2025)

OTC CYTOF
$0.07 +0.00 (+0.00%)
At close: Nov 13, 2026 · 4:00 PM EST
Reported Financials

Altamira Therapeutics Quarterly Cash Flow Statement

Periods 36 quarters
Latest Jun 2025

Altamira Therapeutics cash flow statement data for the quarter ended Jun 2025. This cash flow statement covers 36 quarters of results from Jun 2013 through Jun 2025, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Jun2019 Dec2019 Jun2020 Dec2020 Jun2021 Dec2021 Jun2022 Dec2022 Jun2023 Dec2023 Jun2024 Dec2024 Jun2025
Operating Activities
Net Income
-5.49M-6.25M-4.65M-1.84M-3.13M-3.03M-3.71M
Depreciation and DepletionDep. & Depletion
0.03M0.03M0.03M0.02M0.02M0.02M0.13M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.03M0.03M0.03M0.02M0.02M0.02M0.13M
Share-based CompensationStock Comp.
0.10M0.11M0.10M-0.27M0.16M0.21M0.16M
Gains from Sales and DivestituresGains Divest
-0.16M
Gains from Investment SecuritiesGains Investment
1.55M-0.06M1.69M3.48M0.62M0.23M-2.80M
Other non-cash itemsOther Non-Cash
0.62M0.21M1.18M0.16M0.85M-0.03M0.30M
Non-cash ItemsNon-Cash Items
-5.86M-5.67M-5.38M-4.67M-2.90M-2.88M-0.64M
Change in Working Capital
Change in Account PayablesChange Payables
-0.93M-0.03M0.05M0.16M0.93M-1.18M0.72M
Change in Accrued ExpensesChange Accrued Exp.
0.04M0.60M-1.06M-0.42M-0.74M-0.12M-2.16M
Change in Other Operating AssetsOther Assets Change
0.31M0.13M-0.91M-0.19M0.13M0.20M-0.43M
Change in Other Operating LiabilitiesOther Liabilities Change
0.04M0.04M0.04M0.06M0.06M0.07M-0.22M
Other Working Capital ChangesOther WC Changes
-0.28M-0.09M0.95M0.24M-0.07M-0.13M0.21M
Cash from OperationsCash from Ops.
-6.38M-4.95M-6.54M-5.25M-2.34M-4.08M-1.94M
Investing Activities
Capital ExpendituresCapex
Change in Property, Plant and EquipmentChange in PP&E
Change in IntangiblesChange Intangibless
-0.08M0.30M-0.04M1.92M
Other Investing Activities (as filed)Other investing (as filed)
0.01M0.01M7.10
Cash from Investing ActivitiesCash from Investing
0.01M-0.07M-0.01M-0.02M0.07M-1.88M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment
3.15M-1.50M8.59M-15.49M17.56M
Net Long-Term Debt Issued (Repaid)Net LT Debt
-3.15M1.50M-8.59M15.49M-17.56M
Net Debt Issuances and RepaymentsNet Debt Issuance
-3.15M1.50M-8.59M15.49M-17.56M
Change in Capital Stock
Common Stock IssuedStock Issued
-9.45M5.57M7.12M-10.08M
Net Shares Issued and RepurchasedNet Shares Issued
-9.45M5.57M7.12M-10.08M
Net Equity Issued and RepurchasedNet Equity Issued
-9.45M5.57M7.12M-10.08M
Other financing activities (as filed)
-0.51M0.33M0.10M0.11M-0.52M
Cash from Financing ActivitiesCash from Financing
-0.32M-1.36M1.07M3.12M-6.15M5.00M7.63M
Additional items
Exchange Rate EffectFX Effect
-1.03M0.10M2.84M-0.32M0.15M-0.13M0.03M
Change in Cash
-6.69M-6.37M-5.47M-2.13M-8.52M0.98M0.11M
Ending Cash Balance
27.47M20.81M15.30M13.24M4.43M5.38M5.48M5.93M1.43M41.99M12.77M12.23M1.08M0.39M16.68M55.13M0.73M0.07M1.00M-0.01M
Free Cash FlowFCF
-6.38M-4.95M-6.54M-5.25M-2.34M-4.08M-1.94M
Net Cash FlowNCF
-6.69M-6.37M-5.47M-2.13M-8.52M0.98M3.81M
Interest Paid
-0.32M-0.29M2.12M-0.25M0.59M-0.75M0.84M

Altamira Therapeutics Cash Flow Statement API

Pull Altamira Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CYTOF&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY